We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, John W. Schrader is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
1985 — 1986 |
Schrader, John W |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Autostimulation in Human Hemopoietic Neoplasia @ Walter and Eliza Hall Inst Medical Res
This project aims to test the relevance for human disease in recent observations in the mouse that lead to the hypothesis that transformation of hemopoietic and related cells can result from the abnormal production of a hemopoietic growth factor by a hemopoietic progenitor cell with consequent autostimulation. Major emphasis will be given to the analysis of material from patients with acute nonlymphocytic leukemia and Hodgkin's disease, although other diseases, including myeloproliferative disorders, acute lymphocytic leukemia, and urticaria pigmentosa will also be examined. Tissue culture techniques will be used to test whether the abnormal cells are dependent for their growth on hemopoietic growth factors and whether they are themselves producing these factors. The work will focus on one particular hemopoietic growth factor, the T-cell lymphokine, P-cell stimulating factor, because of its involvement in the murine model of autostimulatory leukemogenesis and because this factor acts on the pluripotential hematopoietic stem cell and progenitor cells of multiple hematopoietic lineages. However, the tissue culture experiments planned will also take into account the possibility that autostimulation could involve other hemopoietic growth factors, which will be detected by their effects on the cell that produces them. Recombinant DNA techniques will be used to investigate whether mRNA for PSF or a related molecule is transcribed in the abnormal cells and whether the PSF gene or its contest is altered. These techniques will permit positive identification of the autostimulatory role of PSF or a related molecule in a given condition, and by analysis of freshly isolated cells establish that abnormal production of PSF is occurring in the patient in vivo and not merely in lines derived from the patient. The importance of determining whether an autostimulatory mechanism is involved in a given human disease lies in the possibility that measures that would block stimulation by the growth factor, e.g., treatment with either analogues of the growth factor that block but do not stimulate, or with monoclonal antibodies directed against the growth factor or its receptor, might interrupt the autostimulation and constitute a relatively selective and nontoxic mode of therapy. (J)
|
0.904 |